NCT07036536 Non-Euploid Embryo Transfer (NEET) Registry
| NCT ID | NCT07036536 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Inception Fertility Research Institute, LLC |
| Condition | Infertility |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-09-23 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-09-23 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The NEET Registry is a registry to track and study the outcomes of non-euploid embryo transfers (NEET) in The Prelude Network
Eligibility Criteria
Inclusion Criteria: * Patient is planning a non-euploid embryo transfer (NEET) at a fertility clinic in The Prelude Network. * Patient has signed informed consent to participate in the registry. Exclusion Criteria: * Not applicable
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07036536 clinical trial?
This trial is open to female participants only, studying Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07036536 currently recruiting?
Yes, NCT07036536 is actively recruiting participants. Contact the research team at research@inceptionllc.com for enrollment information.
Where is the NCT07036536 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07036536 clinical trial?
NCT07036536 is sponsored by Inception Fertility Research Institute, LLC. The trial plans to enroll 1,000 participants.